Sanctura Xr

(trospium)

ApprovedSmall molecule

VVitae Pharmaceuticals Inc., an Allergan affiliate

Sanctura Xr is one of 32 small molecule programs targeting Overactive Bladder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Overactive BladderActive, not recruiting

Urgency Urinary IncontinenceActive, not recruiting

Overactive BladderPreclinical

Active, not recruiting

Urgency Urinary IncontinenceApproved

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

3 2

Botox

AbbVie

Phase 3

3 3

Sanctura Xr

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

2 4

GSK1358820

GSK

Phase 3

1 5

Tolterodine PR

Pfizer

Phase 3

5 6

Oxybutynin Chloride

Mylan Pharmaceuticals Inc

Phase 3

3 7

Vesicare

Astellas

Phase 3

2 8

YM178

Astellas

Phase 3

6 9

SPM 907

Pfizer

Phase 3

5 10

Onabotulinumtoxina 100 UNT

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder2 trials

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed· Astellas logo

Astellas··NCT03602508·5,589 enrolled

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed· Astellas logo

Astellas··NCT03572231·805 enrolled

Urgency Urinary Incontinence1 trial

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

Completed·BBecky Clarkson·Phase 4·NCT04227184·207 enrolled

Regulatory

FDA Approval Timeline[4]

May 28, 2004

SANCTURA

NDA NDA021595

Aug 3, 2007

SANCTURA XR

NDA NDA022103

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for trospium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trospium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trospium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022103). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Vitae Pharmaceuticals Inc., an Allergan affiliate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VVitae Pharmaceuticals Inc., an Allergan affiliate

Sanctura Xr

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder2 trials

Urgency Urinary Incontinence1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News